Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 2/20 | 0.56 |
| ▸ | AKT1 | P31749 | 1/20 | 0.54 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 5/20 | 0.48 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | CIT | O14578 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15432246 | 0.90 | GPR142 (0.56) | GPR142AKT1ROCK2ROCK1LNPEP | |
| SCHEMBL9590958 | 0.79 | AKT1 (0.66) | GPR142AKT1ROCK2ROCK1ALPI | |
| SCHEMBL15432238 | 0.77 | ERAP2 (0.46) | LNPEPERAP2 | |
| SCHEMBL20473200 | 0.77 | GAA (0.57) | GPR142AKT1ROCK2ROCK1ALPI | |
| SCHEMBL20473201 | 0.77 | GAA (0.57) | GPR142AKT1ROCK2ROCK1ALPI | |
| SCHEMBL6527819 | 0.76 | LNPEP (0.56) | GPR142ROCK2LNPEPERAP2ALPI | |
| SCHEMBL28552924 | 0.76 | SMN1; SMN2 (0.54) | GPR142ROCK2ALPIPKMPTGS1 | |
| SCHEMBL21880156 | 0.76 | SMN1; SMN2 (0.54) | GPR142ROCK2ALPIPKMPTGS1 | |
| SCHEMBL2686274 | 0.76 | GPR142 (0.67) | GPR142AKT1ROCK2ROCK1 | |
| SCHEMBL2686269 | 0.76 | GPR142 (0.67) | GPR142AKT1ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140024621-A1 | AMINOPYRIDINE COMPOUNDS AND THEIR USES | MS THERAPEUTICS LIMITED (GB) | 2014-01-23 | — | — | US | disclosed |
| US-20140024621-A1 | AMINOPYRIDINE COMPOUNDS AND THEIR USES | MS THERAPEUTICS LIMITED (GB) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024621-A1 | AMINOPYRIDINE COMPOUNDS AND THEIR USES | DNPEP, PEPD, ANPEP | GPR142 3748/4885AKT1 4278/4885ROCK2 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.